Search

Introduction: Baló’s concentric sclerosis (BCS) is a rare subtype of multiple sclerosis characterized by inflammatory demyelination within the central nervous system. Case Presentation: This case report presents a challenging diagnostic scenario involving a 26-year-old woman diagnosed with BCS. Despite treatment, her condition did not ameliorate, and magnetic resonance imaging (MRI) findings remained unchanged. A subsequent stereotactic biopsy revealed tumefactive Balo disease, highlighting the intricate diagnostic and therapeutic issues surrounding BCS. Conclusion: The juxtacortical location of the BCS lesion, as observed in our case, suggests an unfavourable prognosis due to treatment-resistant seizures.

Depressive disorders are common comorbidities in people living with epilepsy, and they can have a profound effect on both the course of epilepsy and the overall quality of life of those affected. A total of 125 patients diagnosed with epilepsy were recruited from the outpatient care in the Neurology Clinic at the University Clinical Centre of Kosovo, over a 3-month period (October 2023 to December 2023). The Beck Depression Inventory was used to measure the severity of depressive symptoms in these participants. In this study, we observed that 75% of women and 61.4% of men reported mild, moderate, or severe depressive symptoms. According to the severity of depressive symptoms, participants with generalized epilepsy were more likely to report severe depressive symptoms. They represented 59.0% of the participants reporting mild depressive symptoms, 61.5% of the participants reporting moderate depressive symptoms, and 47.6% of the participants reporting severe depression. Assessing and addressing depressive symptoms in individuals with epilepsy through a multidimensional approach and standardized methods is a critical aspect of providing quality care for all patients.

Background. Because of side effects, adherence to the treatment with β interferons in multiple sclerosis (MS) is low, leading to decreased treatment efficacy. This can be challenging, especially in healthcare systems where these medications are the only therapeutic option for the treatment of MS. Materials and Methods. The number of missed doses was calculated as a difference between the number of doses a patient had to withdraw from the treatment start to the cut-off date and the real number of doses taken from the MS unit. Missed doses were compared to gender, age, time since the diagnosis, time from the diagnosis to the treatment start, clinical type of MS, expanded disability status scale (EDSS), and duration of the treatment. Results. The adherence rate during the follow-up period was 73.8%. Patients above 40 years of age (P